Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma

Høyer, Morten; Roed, Henrik; Sengeløv, Lisa; Traberg, Anders; Ohlhuis, Lars; Pedersen, J.; Nellemann, Hanne; Berthelsen, Anne Kiil; Eberholst, Frey; Engelholm, Svend Aage; Maase, Hans von der

doi:10.1016/j.radonc.2004.12.022

Cited by 318 publications

(253 citation statements)

References 22 publications

Supporting

Mentioning

246

Contrasting

Unclassified

Order By: Relevance

“…A detailed description of the principles of treatment has been given previously [6,7,9]. Patients were firmly immobilized by custom made fixation systems that differed between the centres in Aarhus and Copenhagen.…”

Section: Radiotherapymentioning

confidence: 99%

“…Patients were firmly immobilized by custom made fixation systems that differed between the centres in Aarhus and Copenhagen. In Aarhus, patients were immobilised by the stereotactic body frame (SBF; Elekta AB, Stockholm, Sweden) with an external reference coordinate system visible on CT and a diaphragm control that reduces the internal respiration related movement of the liver [6,7,9]. A maximum respiratory movement of the diaphragm of 10 mm during the respiratory cycle evaluated by fluoroscopy was allowed.…”

Section: Radiotherapymentioning

confidence: 99%

See 1 more Smart Citation

Phase II study on stereotactic body radiotherapy of colorectal metastases

et al. 2006

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Radiotherapymentioning

confidence: 99%

Section: Radiotherapymentioning

confidence: 99%

Phase II study on stereotactic body radiotherapy of colorectal metastases

et al. 2006

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 Recently, it has been proposed by some authors to use stereotactic body radiation therapy (SBRT) for the treatment of these tumors. [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] The use of stereotactic techniques is theoretically useful to administer high doses of radiation to the tumor with optimum sparing of organs at risk (OARs). Furthermore, SBRT treatment has other advantages and particularly its brevity.…”

Section: Introductionmentioning

confidence: 99%

Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study

Buwenge

Cilla

Guido

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Six patients developed local progression, and OS was 6 months. A follow-up of the trial reported higher rates of gastric ulceration [48]. More favorable outcomes were reported using smaller treatment fields, more conformal techniques, and hypofractionated protocols.…”

Section: Rt Intensificationmentioning

confidence: 93%

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer

Shaib

Cardona

et al. 2016

The Oncologist

View full text Add to dashboard Cite

Adenocarcinoma of the pancreas remains a highly lethal disease, with less than 5% survival at 5 years. Borderline resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) account for approximately 30% of newly diagnosed cases of PC. The objective of BRPC therapy is to downstage the tumor to allow resection; the objective of LAPC therapy is to control disease and improve survival. There is no consensus on the definitions of BRPC and LAPC, which leads to major limitations in designing clinical trials and evaluating their results. A multimodality approach is always needed to ensure proper utilization and timing of chemotherapy, radiation, and surgery in the management of this disease. Combination chemotherapy regimens (5-fluorouracil, leucovorin, irinotecan, oxaliplatin, and gemcitabine [FOLFIRINOX] and gemcitabine/nab-paclitaxel) have improved overall survival in metastatic disease. The role of combination chemotherapy regimens in BRPC and LAPC is an area of active investigation. There is no consensus on the dose, modality, and role of radiation therapy in the treatment of BRPC and LAPC. This article reviews the literature and highlights the areas of controversy regarding management of BRPC and LAPC. The Oncologist 2016;21:178-187 Implications for Practice: Pancreatic cancer is one of the worst cancers with regard to survival, even at early stages of the disease. This review evaluates all the evidence for the stages in which the cancer is not primarily resectable with surgery, known as borderline resectable or locally advanced unresectable. Recently, advancements in radiation techniques and use of better combination chemotherapies have improved survival and tolerance. There is no consensus on description of stages or treatment sequences (chemotherapy, chemoradiation, radiation), nor on the best chemotherapy regimen. The evidence behind the treatment paradigm for these stages of pancreatic cancer is summarized.

show abstract

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma

Cited by 318 publications

References 22 publications

Phase II study on stereotactic body radiotherapy of colorectal metastases

Phase II study on stereotactic body radiotherapy of colorectal metastases

Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer

Contact Info

Product

Resources

About